Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8026 to 8040 of 8981 results

  1. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Fertility problems: assessment and treatment (CG156)

    This guideline has been updated and replaced by NICE guideline NG257.

    Withdrawn guideline

  3. Diabetes - buccal insulin [ID311]

    Discontinued Reference number: GID-TAG244

    Technology appraisal guidance
    Discontinued

  4. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Discontinued Reference number: GID-TA10961

    Technology appraisal guidance
    Discontinued

  5. Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

    In development Reference number: GID-TA10589 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

    Discontinued Reference number: GID-TA10081

    Technology appraisal guidance
    Discontinued

  7. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued Reference number: GID-TA10126

    Technology appraisal guidance
    Discontinued

  8. Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

    Discontinued Reference number: GID-TA10140

    Technology appraisal guidance
    Discontinued

  9. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued Reference number: GID-TA10148

    Technology appraisal guidance
    Discontinued

  10. Peramivir for treating influenza [ID828]

    Discontinued Reference number: GID-TA10155

    Technology appraisal guidance
    Discontinued

  11. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

    Medical technologies guidance
    Discontinued

  12. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development Reference number: GID-TA11070 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development Reference number: GID-TA11272 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued Reference number: GID-TA10259

    Technology appraisal guidance
    Discontinued

  15. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued Reference number: GID-TAG321

    Technology appraisal guidance
    Discontinued